{"id":1775,"date":"2017-01-17T13:55:00","date_gmt":"2017-01-17T12:55:00","guid":{"rendered":"https:\/\/aliber.org\/web\/2017\/01\/17\/10-grupos-de-investigacion-del-ciberer-en-las-ern\/"},"modified":"2017-01-17T13:55:00","modified_gmt":"2017-01-17T12:55:00","slug":"10-grupos-de-investigacion-del-ciberer-en-las-ern","status":"publish","type":"post","link":"https:\/\/aliber.org\/web\/2017\/01\/17\/10-grupos-de-investigacion-del-ciberer-en-las-ern\/","title":{"rendered":"10 grupos de investigaci\u00f3n del CIBERER en las ERN"},"content":{"rendered":"<p>6 Unidades y 4 Grupos Cl\u00ednicos Vinculados (GCV) al CIBERER se han incorporado a 5 de las 23 Redes Europeas de Referencia recientemente aprobadas, en concreto a las de enfermedades neuromusculares, metab\u00f3licas hereditarias, hematol\u00f3gicas y neurol\u00f3gicas raras.<\/p>\n<p>&#013;<\/p>\n<p>Las Redes Europeas de Referencia (ERN en sus siglas en ingl\u00e9s) son una iniciativa de la Comisi\u00f3n Europea que tiene como objetivo agrupar a centros y unidades especializados en diversos grupos de enfermedades complejas o raras con el objetivo de mejorar la eficacia y la coordinaci\u00f3n en la atenci\u00f3n sanitaria.<\/p>\n<p>&#013;<\/p>\n<p>La ERN en las que est\u00e1n involucrados los investigadores del CIBERER y los grupos participantes son los siguientes:<\/p>\n<p>&#013;<\/p>\n<p>1) European Reference Network for Rare Neuromuscular Diseases (EURO-NMD): <br \/>Isabel Illa. Hospital Sant Pau-U762.<br \/>Juan J. V\u00edlchez. Hospital La Fe-U763.<br \/>Francesc Palau. Hospital San Joan de D\u00e9u-U732.<br \/>Rafael Artuch. Hospital San Joan de D\u00e9u-U703.<br \/>Mireia del Toro. Hospital Vall d\u00b4Hebron-GCV 9.<\/p>\n<p>&#013;<\/p>\n<p>2) European Reference Network for Rare Hereditary Metabolic Disorders (METAB-ERN):<br \/>Miguel \u00c1ngel Mart\u00edn Casanueva. Hospital 12 de Octubre-U723.<br \/>M\u00aa Luz Couce. Hospital de Santiago de Compostela-GCV 5.<br \/>Luis Ald\u00e1miz Echevarr\u00eda. Hospital de Cruces-GCV 10.<br \/>Mireia del Toro. Hospital Vall d\u00b4Hebron-GCV 9.<br \/>Rafael Artuch. Hospital San Joan de D\u00e9u-U703.<\/p>\n<p>&#013;<\/p>\n<p>3) European Reference Network on Rare Neurological Diseases (ERN-RND):<br \/>Rafael Artuch. Hospital San Joan de Deu-U703.<br \/>Mireia del Toro. Hospital Vall d\u00b4Hebron-GCV 9.<\/p>\n<p>&#013;<\/p>\n<p>4) European Reference Network on Rare Hematological Diseases (EuroBloodNet):<br \/>Joan Llu\u00eds Vives Corrons. Hospital Cl\u00ednic-GCV 20.<\/p>\n<p>&#013;<\/p>\n<p>5) European Reference Network on Rare Endocrine Conditions (Endo-ERN):<br \/>Antonio Carrascosa. Vall d&#8217;Hebron Institut de Recerca-U712.<\/p>\n<p>&#013;<\/p>\n<p>En esta convocatoria de ERN de 2016, se recibieron 24 solicitudes que involucraban 26 estados miembros, 370 hospitales y casi 1.000 unidades de alta especializaci\u00f3n.<\/p>\n<p>&#013;<\/p>\n<p>Las 23 redes aprobadas son las siguientes:<br \/>1. BOND &#8211; European Reference Network on Rare Bone Disorders<br \/>2. CRANIO &#8211; European Reference Network on Rare craniofacial anomalies and ENT disorders<br \/>3. Endo-ERN &#8211; European Reference Network on Rare Endocrine Conditions<br \/>4. EpiCARE &#8211; European Reference Network on Rare and Complex Epilepsies<br \/>5. ERKNet &#8211; European Rare Kidney Diseases Reference Network<br \/>6. ERN-RND &#8211; European Reference Network on Rare Neurological Diseases<br \/>7. ERNICA &#8211; European Reference Network on Rare inherited and congenital anomalies<br \/>8. ERN-LUNG &#8211; European Reference Network on Rare Respiratory Diseases<br \/>9. ERN-Skin &#8211; European Reference Network on Rare and Undiagnosed Skin Disorders<br \/>10. EURACAN &#8211; European Reference Network on Rare Adult Cancers (solid tumors)<br \/>11. EuroBloodNet &#8211; European Reference Network on Rare Hematological Diseases<br \/>12. EURO-NMD &#8211; European Reference Network for Rare Neuromuscular Diseases<br \/>13. ERN-EYE &#8211; European Reference Network on Rare Eye Diseases<br \/>14. ERN GENTURIS<br \/>European Reference Network on GENetic TUmour RIsk Syndromes<br \/>15. GUARD-HEART &#8211; Gateway to Uncommon And Rare Diseases of the HEART<br \/>16. ITHACA &#8211; European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability<br \/>17. MetabERN &#8211; European Reference Network for Rare Hereditary Metabolic Disorders<br \/>18. PaedCan-ERN &#8211; European Reference Network for Paediatric Cancer (haemato-oncology)<br \/>19. RARE-LIVER &#8211; European Reference Network on Rare Hepatological Diseases<br \/>20. ReCONNET &#8211; Rare Connective Tissue and Musculoskeletal Diseases Network<br \/>21. RITA &#8211; Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases Network<br \/>22. TRANSCHILD &#8211; European Reference Network on Transplantation in Children (incl. HSCT, heart, kidney, liver, intestinal, lung andmultiorgan)<br \/>23. VASCern &#8211; European Reference Network on Rare Multisystemic Vascular Diseases<\/p>\n<p>&#013;<br \/>\nSource: FEDER<\/p>\n","protected":false},"excerpt":{"rendered":"<p>6 Unidades y 4 Grupos Cl\u00ednicos Vinculados (GCV) al CIBERER se han incorporado a 5 de las 23 Redes Europeas de Referencia recientemente aprobadas, en concreto a las de enfermedades<a href=\"https:\/\/aliber.org\/web\/2017\/01\/17\/10-grupos-de-investigacion-del-ciberer-en-las-ern\/\">[&#8230;]<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"false","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[7],"tags":[24],"class_list":["post-1775","post","type-post","status-publish","format-standard","hentry","category-socios","tag-enfermedades-raras"],"_links":{"self":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/posts\/1775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/comments?post=1775"}],"version-history":[{"count":0,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/posts\/1775\/revisions"}],"wp:attachment":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/media?parent=1775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/categories?post=1775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/tags?post=1775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}